Renascience

Renascience P/TBV

The Price to Tangible Book Value (P/TBV) of Renascience (4889.T) as of Oct 27, 2026 is 7.28. In the previous year, Price to Tangible Book Value (P/TBV) was 14.06 — a change of -48.23% (lower).

P/TBV

7.28

YoY

-48.23%

Last updated:

Price to Tangible Book Value (P/TBV) of Renascience is 2026 7.28 . Price to Tangible Book Value (P/TBV) of Renascience was 2025 14.06 . It decreases by -48.23% lower compared to the previous year.

The Renascience P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2020
39.88 JPY
Jan 1, 2021
44.11 JPY
Jan 1, 2022
10.99 JPY
Jan 1, 2023
12.97 JPY
Jan 1, 2024
15.05 JPY
Jan 1, 2025
14.06 JPY
Jan 1, 2026
7.28 JPY
The Renascience P/TBV history
YEARP/TBVYoY
7.28-48.23%
14.06-6.59%
15.05+16.07%
12.97+18.02%
10.99-75.09%
44.11+10.59%
39.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Price to Tangible Book Value (P/TBV) of Renascience is 7.28 in 2026.

Price to Tangible Book Value (P/TBV) of Renascience changed from 14.06 to 7.28, representing a -48.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Renascience since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Renascience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Renascience

All Key Metrics — Renascience